Cytoimmune Therapeutics Inc

GeneFluidics, based in Duarte, CA, is a pioneering company that was established in 2000 with the aim of developing a cutting-edge testing system to enhance global health. By combining innovative bionano and microfluidic technologies, their revolutionary platform allows for complex tests that are typically conducted in laboratories by skilled technicians to be performed by anyone, anywhere. With a simple process that involves introducing a raw sample into a disposable cartridge and waiting for the results, GeneFluidics' platform offers fast, accurate, and user-friendly testing solutions. With a focus on nanotechnology-enabled analyte detection and microfluidic-based automated sample preparation, GeneFluidics' platform was initially conceived as part of a biodefense program. Over the years, the company has achieved significant milestones, including being selected as a finalist for the Antimicrobial Resistance Diagnostic (AMR) Challenge Step 2 and obtaining CE-IVD marking for their UtiMax uropathogen identification and antimicrobial susceptibility testing (AST). Additionally, GeneFluidics has received funding from the National Institute of Allergy and Infectious Diseases (NIAID) for the development and clinical validation of diagnostics, further solidifying their position as a leader in the field.Generated from the website

Pace Diagnostics is an emerging biotechnology company based in Monrovia, CA, dedicated to the research, development, manufacturing, and marketing of cutting-edge diagnostics. With a focus on point-of-care rapid diagnostics, their innovative approach combines novel biomarkers with advanced diagnostic platforms to create breakthrough solutions for healthcare improvement. Supported by grants and contracts from the US Federal Government, Pace Diagnostics aims to revolutionize healthcare by providing instant diagnostics anywhere in the world. Their comprehensive portfolio includes the Tuberculosis Triage Screening Test, COVID-19 Antigen Rapid Detection Test, and Lung Cancer Early Detection Test, offering innovative solutions for early disease detection and screening.Generated from the website

Paradigm Immunotherapeutics, Inc., based in Monrovia, CA, focuses on developing groundbreaking technologies aimed at combating BSL 3 and 4 infectious agents, including Ebola, as well as innovative treatments for immune-mediated diseases. The company operates at the forefront of medical advancements, although the co-development of intellectual property necessitates limited public disclosure. For accredited investors, Paradigm provides access to essential materials such as a pitch deck, term sheet, team information, an executive summary, FAQs, and budget details from 2016-2018 through a designated platform. This approach underscores the company’s commitment to fostering investment in its pioneering scientific endeavors. Generated from the website